May 08, 2026

Hella Bühler Prize Awarded to DKFZ Researcher Angelika Feldmann

Hella Bühler Prize Awarded to DKFZ Researcher Angelika Feldmann

For her groundbreaking research on the regulation of gene activity, Angelika Feldmann has been awarded the 2026 Hella Bühler Prize, which comes with a grant of €100,000. Presented by Heidelberg University, the award is intended for young researchers in the Heidelberg research community who have already distinguished themselves through outstanding scientific achievements in cancer research.

(c) Privat

At the heart of Angelika Feldmann’s research is the question of how certain regulatory DNA sequences act as enhancers and falsely activate genes or increase their activity. This mechanism can contribute to the “enhanced” genes triggering uncontrolled cell growth as oncogenes. Angelika Feldmann leads the “Mechanisms of Genome Control” early-career research group at the German Cancer Research Center (DKFZ). 

Oncogenes are overactivated versions of normal genes that lead to uncontrolled cell growth. How so-called “enhancer hijacking” triggers this activation is the subject of Angelika Feldmann’s research. In this mechanism, enhancers bind to specific DNA regions that, as promoters, control the initiation of gene activity. Although the enhancers are often located far away from the gene in question, they can establish contact with the promoter through DNA folding and loop formation. To date, it is unknown whether and when such physical contacts are actually necessary to falsely activate genes or amplify their activity.

Elucidating the mechanisms behind the excessive transcriptional activity of oncogenes in detail is the goal of Feldmann’s project, “The Role of Promoter Contacts in Enhancer Function during the Activation of Developmental and Tumor Genes.” To this end, the researcher is collaborating with Dominik Niopek from the Institute of Pharmacy and Molecular Biotechnology at Heidelberg University.

Angelika Feldmann studied molecular medicine at the University of Freiburg and earned her Ph.D. in genetics in 2014 at the Friedrich Miescher Institute for Biomedical Research in Basel. She subsequently conducted research at the University of Oxford before joining the German Cancer Research Center in 2021 as the head of a Helmholtz Junior Research Group. The scientist has received numerous awards and grants for her research, including an ERC Starting Grant from the European Research Council (ERC) in 2023. With funding from the ERC, Feldmann is investigating the molecular processes necessary to ensure that, during an organism’s development, all cells can read the correct genes at the right time.

The research prize, endowed by the Heidelberg dentist Hella Bühler (1910–2002), is intended for early-career researchers at Heidelberg University or for young researchers affiliated with Ruperto Carola through scientific collaboration. The award is intended to support the recipients in the early stages of their careers as they continue and deepen their already outstanding work in the field of cancer research. It is awarded by the University and is one of the most highly endowed awards in the field of cancer research in Germany. The award ceremony will take place on May 7, 2026.

Source: Press release from Heidelberg University

Our latest News

discover more
The Heidelberg and Mannheim University Hospitals consortium has taken first place in the Stern hospital rankings

The Heidelberg and Mannheim University Hospitals consortium has taken first place in the Stern hospital rankings

For the first time in 14 years, there has been a change at the top of the hospital rankings, which are published annually by the MINQ Institute in collaboration with Stern. In its very first year of existence, the Heidelberg and Mannheim University Hospitals Consortium has taken first place. More information in German below: Zusammen […]

Presentation of the EY German Biotechnology Report 2026 in Heidelberg: Strong Innovation Ecosystems Are Key to Scaling Innovation

Presentation of the EY German Biotechnology Report 2026 in Heidelberg: Strong Innovation Ecosystems Are Key to Scaling Innovation

Heidelberg, 11 June 2026 – Germany continues to produce world-class science, breakthrough technologies and highly innovative biotechnology companies. However, the challenge is no longer generating innovation – it is creating the conditions that allow innovation to scale. This was one of the central messages emerging from the presentation of the EY German Biotechnology Report 2026, […]

CELASC 2026 presentation: Impact of topical lidocaine-prilocaine analgesia on pain-induced grooming after ear notching of mice

CELASC 2026 presentation: Impact of topical lidocaine-prilocaine analgesia on pain-induced grooming after ear notching of mice

Finnish animal welfare legislation (Government Decree 1165/2023) effective as of January 1, 2024, requires establishments to apply “appropriate pain relief” in association with ear notching identification method of laboratory rodents(1). However, there is a lack of scientific evidence whether the benefits of applying analgesia outweigh the additional stress related to handling and drug administration. Our […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp